SynthesisBreast cancer research : BCR2023
Risks of second non-breast primaries following breast cancer in women: a systematic review and meta-analysis.
Synthesis in Breast cancer research : BCR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07253987 (Cancer Survivors Program), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cancer Survivors Program: Effectiveness of Monitoring Adverse Events After Completion of Curative Treatment for Breast and Prostate Cancer
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Bladder cancer risk factors: a comprehensive umbrella review of meta-analyses.International journal of surgery (London, England) · 2026Pooled it
- Ovarian Metastasis from Invasive Lobular Carcinoma of the Breast: A 6-Case Series with Emphasis on Diagnostic Challenges and the Value of Biopsy.Diagnostics (Basel, Switzerland) · 2026Article
- Development of a risk prediction model for second primary thyroid cancer in female breast cancer patients based on machine learning algorithms.Scientific reports · 2026Article
- Beyond the Beam: Multimodal Imaging and Surveillance of Post-Radiotherapy Changes in the Breast.Life (Basel, Switzerland) · 2026Review
- Clinicopathological features and diagnostic intervals of second primary breast cancer following a prior malignancy: a single-center retrospective study.Frontiers in oncology · 2026Article
- Ten-year risk of second primary malignancies among chemotherapy-treated early-stage breast cancer survivors: a multicentre cohort study from the Turkish Oncology Group.Frontiers in oncology · 2026Article
- Breast cancer as the first primary malignancy: clinical pathological characteristics of common cancer combinations.Discover oncology · 2025Review
- Comorbidity burden and risk of second primary non-breast cancer in breast cancer survivors.Cancer epidemiology · 2025Article
- Risk factors of breast cancer patients developing multiple primary cancers: a retrospective study and establishing/testing of machine learning models.BMC medical informatics and decision making · 2025Article
- Molecular Marker Discovery and Evaluation: EGF rs1897990 and rs1524106 Variants in a China Lung Adenocarcinoma Young Population.The clinical respiratory journal · 2025Article
- Socio-economic inequalities in second primary cancer incidence: A competing risks analysis of women with breast cancer in England between 2000 and 2018.International journal of cancer · 2025Article
- Long-term outcomes of bilateral salpingo-oophorectomy in women with personal history of breast cancer.BMJ oncology · 2025Article
- Causal effect between breast cancer and ovarian cancer: a two-sample mendelian randomization study.BMC cancer · 2024Article
- Second primary non-breast cancers in young breast cancer survivors.Breast cancer research and treatment · 2024Article
- Incidence and Characteristics of Multiple Primary Cancers: A 20-Year Retrospective Study of a Single Cancer Center in Korea.Cancers · 2024Article
- Risks of second primary cancers among 584,965 female and male breast cancer survivors in England: a 25-year retrospective cohort study.The Lancet regional health. Europe · 2024Article
- Second primary cancers among females with a first primary breast cancer: a population-based study in Northern Portugal.Breast cancer research and treatment · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundSecond primary cancer incidence is rising among breast cancer survivors. We examined the risks of non-breast second primaries, in combination and at specific cancer sites, through a systematic review and meta-analysis.
methodsWe conducted a systematic search of PubMed, Embase, and Web of Science, seeking studies published by March 2022. We included studies that reported standardized incidence ratios (SIRs), with associated standard errors, assessing the combined risk of second non-breast primaries following breast cancer. We performed meta-analyses of combined second primary risks, stratifying by age, follow-up duration, and geographic region. We also assessed second primary risks at several specific sites, stratifying by age. The inverse variance method with DerSimonian-Laird estimators was used in all meta-analyses, assuming a random-effects model. Associated biases and study quality were evaluated using the Newcastle-Ottawa scale.
resultsOne prospective and twenty-seven retrospective cohort studies were identified. SIRs for second non-breast primaries combined ranged from 0.84 to 1.84. The summary SIR estimate was 1.24 (95% CI 1.14-1.36, I
conclusionsBreast cancer survivors are at significantly increased risk of second primaries at many sites. Risks are higher for those diagnosed with breast cancer before age 50 and in Asian breast cancer survivors compared to European breast cancer survivors. This study is limited by a lack of data on potentially confounding variables. The conclusions may inform clinical management decisions following breast cancer, although specific clinical recommendations lie outside the scope of this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.